|
Valoración de DCF de Briacell Therapeutics Corp. (BCTX)
CA | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
BriaCell Therapeutics Corp. (BCTX) Bundle
¡Obtenga información sobre su análisis de valoración de Briacell Therapeutics Corp. (BCTX) utilizando nuestra calculadora DCF de vanguardia! Esta plantilla de Excel viene precargada con datos reales (BCTX), lo que le brinda la flexibilidad de ajustar los pronósticos y los supuestos para determinar con precisión el valor intrínseco de Briacell Therapeutics Corp.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -2.7 | -6.0 | -10.5 | -21.2 | -3.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .0 | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -2.8 | -6.0 | -10.5 | -21.2 | -3.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .0 | 39.6 | 28.4 | 14.7 | .6 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .5 | .9 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .0 | .1 | .3 | .8 | 5.0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | -.3 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -2.8 | 4.7 | -10.5 | -21.2 | -3.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2.7 | 4.9 | -10.3 | -21.3 | .1 | -4.0 | .0 | .0 | .0 | .0 |
| WACC, % | 12.85 | 12.85 | 12.85 | 12.85 | 12.85 | 12.85 | 12.85 | 12.85 | 12.85 | 12.85 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | -3 | |||||||||
| Diluted Shares Outstanding, MM | 16 | |||||||||
| Equity Value Per Share | -0.18 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real BCTX financials.
- Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast parameters such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effects of your inputs on BriaCell's valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as clinical trial outcomes, market penetration rates, and operational costs.
- Instant Valuation Analysis: Quickly computes intrinsic value, NPV, and other financial metrics.
- High-Precision Accuracy: Leverages BriaCell's real-world data for credible valuation results.
- Effortless Scenario Simulation: Evaluate various hypotheses and analyze results with ease.
- Efficiency Booster: Avoid the hassle of creating intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered BriaCell Therapeutics Corp. (BCTX) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for BriaCell Therapeutics Corp.'s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator?
- User-Friendly Interface: Perfect for both novice and experienced users.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Feedback: Observe immediate updates to BriaCell Therapeutics Corp.'s (BCTX) valuation as you change inputs.
- Preloaded Data: Comes with BriaCell’s actual financial information for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Accurately assess BriaCell Therapeutics Corp.'s (BCTX) fair value prior to making investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and analysis specific to BriaCell Therapeutics Corp. (BCTX).
- Consultants: Efficiently modify the template for valuation reports tailored to BriaCell Therapeutics Corp. (BCTX) clients.
- Entrepreneurs: Acquire knowledge about financial modeling practices employed by leading biotech firms like BriaCell Therapeutics Corp. (BCTX).
- Educators: Implement it as a teaching resource to illustrate valuation techniques relevant to the biotech sector.
What the Template Contains
- Preloaded BCTX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.